Sleep Quality in Hemodialysis Patients According to Renal Anemia Treatment Outcomes
DOI:
https://doi.org/10.63623/mybdry40Keywords:
Hemodialysis, Anemia, Epoetin, Erythropoietin, Sleep qualityAbstract
Backgound: We assessed the impact of renal anemia treatment on sleep quality among hemodialysis (HD) patients. Methods: To be included in the study, patients had to have received epoetin (EPO) therapy within the past year. Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI), with poor sleepers defined as those with a global PSQI score > 5. The target hemoglobin level (THb) was defined as a hemoglobin (Hb) level greater than 11.0 g/dL in the three months preceding the sleep survey. Results: A total of 78 patients were included, with a median age of 59.0 years. The mean HD vintage was 50.5 months. THb levels were achieved in 43 patients (55.1%), while 46 patients (59.0%) were identified as poor sleepers. Median PSQI score was 6 (4–11) in patients who achieved THb, compared with 7 (4–9) in those who did not (p=0.217). Mean Hb level was 11.2±1.3 g/dL among poor sleepers and 11.3±1.2 g/dL among non-poor sleepers (p=0.603). There was no significant correlation between PSQI score and Hb level (p=0.955). The frequency of poor sleepers was significantly higher in patients receiving EPO therapy (68.0%) compared to those not receiving EPO therapy (42.8%) (p=0.027). Furthermore, EPO use was identified as an independent risk factor for poor sleep quality (OR: 2.822, 95% CI: 1.029–7.737). Neither Hb level nor achieving THb were found to be independent predictors of poor sleep quality. Conclusion: Successful anemia treatment did not have a positive impact on sleep quality among HD patients.
References
[1]Bello AK, Okpechi IG, Osman MA, Cho Y, Htay H, Jha V, et al. Epidemiology of haemodialysis outcomes. Nature Reviews Nephrology, 2022, 18(6), 378-395. DOI: 10.1038/s41581-022-00542-7
[2]Himmelfarb J. Hemodialysis complications. American Journal of Kidney Diseases, 2005, 45(6), 1122-1131. DOI: 10.1053/j.ajkd.2005.02.031
[3]Parker KP. Sleep disturbances in dialysis patients. Sleep Medicine Reviews, 2003, 7(2), 131-143. DOI: 10.1053/smrv.2001.0240
[4]Gul A, Aoun N, Trayner Jr EM. Unresolved issues in dialysis: Why do patients sleep on dialysis? Wiley Online Library, 2006, 152-157. DOI: 10.1111/j.1525-139X.2006.00142.x
[5]Alshammari B, Alkubati SA, Pasay-An E, Alrasheeday A, Alshammari HB, Asiri SM, et al. Sleep quality and its affecting factors among hemodialysis patients: A multicenter cross-sectional study. Healthcare (Basel). 2023, 11(18), 2536. DOI: 10.3390/healthcare11182536
[6]Collins AJ, Ma JZ, Ebben J. Impact of hematocrit on morbidity and mortality. Seminars in Nephrology, 2000, 20(4), 345-349.
[7]Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. Journal of the American Society of Nephrology, 1999, 10(3), 610-619. DOI: 10.1681/asn.v103610
[8]Portolés J, Martín L, Broseta JJ, Cases A. Anemia in chronic kidney disease: From pathophysiology and current treatments, to future agents. Frontiers in Medicine, 2021, 8, 642296. DOI: 10.3389/fmed.2021.642296
[9]Babitt JL, Lin HY. Mechanisms of Anemia in CKD. Journal of the American Society of Nephrology, 2012, 23(10), 1631-1634. DOI: 10.1681/ASN.2011111078
[10]Roger SD, Tio M, Park HC, Choong HL, Goh B, Cushway TR, et al. Intravenous iron and erythropoiesis‐stimulating agents in haemodialysis: A systematic review and meta‐analysis. Nephrology, 2017, 22(12), 969-976. DOI: 10.1111/nep.12940
[11]Hougen I, Collister D, Bourrier M, Ferguson T, Hochheim L, Komenda P, et al. Safety of intravenous iron in dialysis: A systematic review and meta-analysis. Clinical Journal of the American Society of Nephrology, 2018, 13(3), 457-467. DOI: 10.2215/CJN.05390517
[12]Biggar P, Kim G-H. Treatment of renal anemia: Erythropoiesis stimulating agents and beyond. Kidney Research and Clinical Practice, 2017, 36(3), 209-223. DOI: 10.23876/j.krcp.2017.36.3.209
[13]Chen N, Hao C, Liu B-C, Lin H, Wang C, Xing C, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. New England Journal of Medicine, 2019, 381(11), 1011-1022. DOI: 10.1056/NEJMoa1901713
[14]Wish JB. Treatment of anemia in kidney disease: Beyond erythropoietin. Kidney International Reports, 2021, 6(10), 2540-2553. DOI: 10.1016/j.ekir.2021.05.028
[15]Buysse DJ, Reynolds III CF, Monk TH, Berman SR, Kupfer DJ. The pittsburgh sleep quality index: A new instrument for psychiatric practice and research. Psychiatry Research, 1989, 28(2), 193-213. DOI: 10.1016/0165-1781(89)90047-4
[16]Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume kt/v: An analysis of error. Journal of the American Society of Nephrology, 1993, 4(5), 1205-1213. DOI: 10.1681/ASN.V451205
[17]Bonomini M, Del Vecchio L, Sirolli V, Locatelli F. New treatment approaches for the anemia of CKD. American Journal of Kidney Diseases, 2016, 67(1), 133-142. DOI: 10.1053/j.ajkd.2015.06.030
[18]Li PKT, Choy ASM, Bavanandan S, Chen W, Foo M, Kanjanabuch T, et al. Anemia management in peritoneal dialysis: Perspectives from the asia pacific region. Kidney Medicine, 2021, 3(3), 405-411. DOI: 10.1016/j.xkme.2021.01.011
[19]Rossert J, Gassmann-Mayer C, Frei D, McClellan W. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. Nephrology Dialysis Transplantation, 2007, 22(3), 794-800. DOI: 10.1093/ndt/gfl716
[20]Jelkmann W. Molecular biology of erythropoietin. Internal Medicine, 2004, 43(8), 649-659. DOI: 10.2169/internalmedicine.43.649
[21]Koury MJ, Haase VH. Anaemia in kidney disease: Harnessing hypoxia responses for therapy. Nature Reviews Nephrology, 2015, 11(7), 394-410. DOI: 10.1038/nrneph.2015.82
[22]McMurray J, Parfrey P, Adamson JW, Aljama P, Berns JS, Bohlius J, et al. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney International Supplements, 2012, 2(4), 279-335. DOI: 10.1038/kisup.2012.37
[23]Robles NR. The safety of erythropoiesis-stimulating agents for the treatment of anemia resulting from chronic kidney disease. Clinical Drug Investigation, 2016, 36, 421-431. DOI: 10.1007/s40261-016-0378-y
[24]Sabbatini M, Pisani A, Mirenghi F, Cianciaruso B, Crispo A. The impact of haemoglobin on the quality of sleep in haemodialysis patients: Which is the truth? Nephrology Dialysis Transplantation, 2003, 18(9), 1947-1948. DOI: 10.1093/ndt/gfg257
[25]Jamelo JP, Valdepenas AN, Fadriquela DL, Gueco I. Quality of sleep and the quality of life in chronic kidney disease patients undergoing hemodialysis in a tertiary hospital in the philippines. Nephrology Dialysis Transplantation, 2024, 39(Supplement_1). DOI: 10.1093/ndt/gfae069.1421
[26]Vittori DC, Chamorro ME, Hernández YV, Maltaneri RE, Nesse AB. Erythropoietin and derivatives: Potential beneficial effects on the brain. Journal of Neurochemistry, 2021, 158(5), 1032-1057. DOI: 10.1111/jnc.15475
[27]John MJ, Jaison V, Jain K, Kakkar N, Jacob JJ. Erythropoietin use and abuse. Indian Journal of Endocrinology and Metabolism, 2012, 16(2), 220-227. DOI: 10.4103/2230-8210.93739
[28]Robinson BM, Joffe MM, Berns JS, Pisoni RL, Port FK, Feldman HI. Anemia and mortality in hemodialysis patients: Accounting for morbidity and treatment variables updated over time. Kidney International, 2005, 68(5), 2323-2330. DOI: 10.1111/j.1523-1755.2005.00693.x
[29]Bale C, Douglas A, Jegatheesan D, Pham L, Huynh S, Mulay A, et al. Psychosocial factors in end‐stage kidney disease patients at a tertiary hospital in Australia. International Journal of Nephrology, 2016, 2016(1), 2051586. DOI: 10.1155/2016/2051586
[30]Peng Y, Huang H, Liao Y, Diao Y, Lin C, Liu Y, et al. Risk factors affecting the sleep quality of patients on dialysis: A single-center cross-sectional study. Medicine, 2024, 103(13), e37577. DOI: 10.1097/MD.0000000000037577
[31]Tosun N, Kalender N, Cinar FI, Bagcivan G, Yenicesu M, Dikici D, et al. Relationship between dialysis adequacy and sleep quality in haemodialysis patients. Journal of Clinical Nursing, 2015, 24(19-20), 2936-2944. DOI: 10.1111/jocn.12908
[32]Knobbe TJ, Kremer D, Eisenga MF, van Londen M, Annema C, Bültmann U, et al. Sleep quality, fatigue, societal participation and health-related quality of life in kidney transplant recipients: A cross-sectional and longitudinal cohort study. Nephrology Dialysis Transplantation, 2023, 39(1), 74-83. DOI: 10.1093/ndt/gfad148
[33]Chang SY, Yang TC. Sleep quality and associated factors in hemodialysis patients. Acta Nephrologica, 2011, 25(3), 97-104.
[34]Turkmen K, Yazici R, Solak Y, Guney I, Altintepe L, Yeksan M, et al. Health‐related qualıty of lıfe, sleep qualıty, and depressıon in peritoneal dialysis and hemodialysis patients. Hemodialysis International, 2012, 16(2), 198-206. DOI: 10.1111/j.1542-4758.2011.00648.x
[35]Masoumi M, Naini AE, Aghaghazvini R, Amra B, Gholamrezaei A. Sleep quality in patients on maintenance hemodialysis and peritoneal dialysis. International Journal of Preventive Medicine, 2013, 4(2), 165-172.
[36]Edalat-Nejad M, Haqhverdi F, Hossein-Tabar T, Ahmadian M. Melatonin improves sleep quality in hemodialysis patients. Indian Journal of Nephrology, 2013, 23(4), 264-269. DOI: 10.4103/0971-4065.114488
[37]Sohn SI, Kim DH, Lee MY, Cho YW. The reliability and validity of the korean version of the pittsburgh sleep quality index. Sleep and Breathing, 2012, 16, 803-812. DOI: 10.1007/s11325-011-0579-9
[38]Eloot S, Holvoet E, Dequidt C, Maertens S-J, Vanommeslaeghe F, Van Biesen W. The complexity of sleep disorders in dialysis patients. Clinical Kidney Journal, 2021, 14(9), 2029-2036. DOI: 10.1093/ckj/sfaa258
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Elif Basaran, Cihan Uysal (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
